Levetiracetam Overview
Levetiracetam is an effective antiepileptic drug approved for adjunctive treatment of partial-onset seizures, myoclonic seizures in juvenile myoclonic epilepsy, and primary generalized tonic-clonic seizures, with a favorable pharmacokinetic profile requiring dose adjustment only in renal impairment. 1
Indications
Levetiracetam is FDA-approved for:
- Adjunctive therapy for partial-onset seizures in adults and children ≥4 years 1
- Adjunctive therapy for myoclonic seizures associated with juvenile myoclonic epilepsy 2
- Adjunctive therapy for primary generalized tonic-clonic seizures in idiopathic generalized epilepsy 2
- Monotherapy for partial-onset seizures with or without secondary generalization 2
The drug has demonstrated efficacy across multiple seizure types, with responder rates (≥50% seizure reduction) of 22-33% at 1,000 mg/day, 31-34% at 2,000 mg/day, and 39.8% at 3,000 mg/day in adults with refractory partial epilepsy 3. In pediatric patients, responder rates reached 52% in open trials 3.
Adult Dosing
Standard dosing:
- Initial dose: 500 mg twice daily (1,000 mg/day total)
- Titration: Increase by 500-1,000 mg/day every 2-4 weeks based on response
- Maintenance range: 1,000-3,000 mg/day divided twice daily 1
- Maximum dose: 3,000 mg/day
The pharmacokinetics are linear from 500-5,000 mg, with steady state achieved after 2 days of twice-daily dosing 1. Higher doses show increased efficacy but also increased side effects—the 3,000 mg/day dose achieved the highest responder rate (39.8%) but seizure-free rates remained modest at 8% 3.
Critical dosing principle: Start low and titrate slowly to maximize tolerability. Rapid titration (initiating at 2,000-4,000 mg without titration) significantly increases somnolence and asthenia 3.
Pediatric Dosing
For children ≥4 years:
- Initial dose: 10 mg/kg twice daily (20 mg/kg/day total)
- Titration: Increase by 10 mg/kg twice daily every 2 weeks
- Maintenance dose: 30 mg/kg twice daily (60 mg/kg/day total) 1
Pediatric patients require 130-140% of adult doses on a per-weight basis due to approximately 40% higher body weight-adjusted clearance compared to adults 1, 4. The pharmacokinetics in children aged 4-12 years are linear between 20-60 mg/kg/day, with a half-life of approximately 5 hours 1.
Important caveat: When co-administered with enzyme-inducing antiepileptics (e.g., carbamazepine), levetiracetam clearance increases by approximately 22%, potentially requiring higher doses 1.
Renal Impairment Dosing
Levetiracetam clearance is directly correlated with creatinine clearance, requiring mandatory dose adjustment in renal dysfunction 1:
- Mild impairment (CrCl 50-80 mL/min): 500-1,000 mg twice daily (40% reduction in clearance) 1, 5
- Moderate impairment (CrCl 30-50 mL/min): 250-750 mg twice daily (50% reduction in clearance) 1, 6
- Severe impairment (CrCl <30 mL/min): 250-500 mg twice daily (60% reduction in clearance) 1, 5
- End-stage renal disease (ESRD): 500-1,000 mg once daily with supplemental 250-500 mg dose after each dialysis session 1, 5
Approximately 50% of levetiracetam is removed during a standard 4-hour hemodialysis procedure, necessitating post-dialysis supplementation 1. Recent modeling studies confirm these recommendations achieve target therapeutic concentrations 5, 7.
Hepatic Impairment Dosing
No dose adjustment is required for hepatic impairment 1. In severe hepatic impairment (Child-Pugh C), total body clearance is reduced to 50% of normal, but this is primarily due to concurrent decreased renal clearance rather than hepatic dysfunction 1. Levetiracetam undergoes minimal hepatic metabolism (only 24% via non-cytochrome P450 enzymatic hydrolysis) 1.
Elderly Dosing
Elderly patients require dose adjustment based on renal function, not age alone 1. Total body clearance decreases by 38% and half-life increases by 2.5 hours in elderly patients, primarily due to age-related decline in renal function 1. Monitor creatinine clearance and adjust doses according to renal impairment guidelines above.
Side Effects
Most common adverse events (occurring in clinical trials):
- Somnolence
- Asthenia (weakness)
- Dizziness
- Headache
- Infection 3
Behavioral and psychiatric effects:
- Behavioral problems, depression, and psychosis have been reported 3
- These effects occur more frequently in patients with pre-existing psychiatric history 8
- Recent data suggests neuropsychiatric events occur in only 3.6% of patients, with levetiracetam being well-tolerated even in vulnerable populations 8
Rare but serious adverse effects:
- Rhabdomyolysis: Rare but clinically significant, potentially dose-related 9
- Stevens-Johnson syndrome (one case reported in pediatric trials) 3
- Hypohidrosis (decreased sweating) in pediatric patients 3
Important safety consideration: Discontinuation rates due to adverse events ranged from 7-13% with active drug versus 5-8% with placebo, indicating generally good tolerability 3. However, slow titration is essential—faster titration increases side effects without improving efficacy 3.
Contraindications
Levetiracetam has no absolute contraindications beyond hypersensitivity to the drug or its components 1. However, exercise caution in:
- Pregnancy: Use only if potential benefit justifies potential risk to fetus. Enroll patients in the North American Antiepileptic Drug (NAAED) pregnancy registry (1-888-233-2334) 1
- Breastfeeding: Levetiracetam is excreted in breast milk; weigh risks versus benefits 1
- Renal impairment: Mandatory dose adjustment required 1
- Psychiatric history: Monitor closely for behavioral changes 8
Pharmacokinetic Advantages
Levetiracetam offers significant practical advantages:
- Rapid, complete absorption (100% oral bioavailability) with peak levels at 1 hour 1
- Minimal protein binding (<10%), eliminating protein-binding drug interactions 1
- No cytochrome P450 involvement, avoiding most drug-drug interactions 1
- Linear pharmacokinetics allowing predictable dose adjustments 1
- No effect on other antiepileptics: Does not alter levels of carbamazepine, valproic acid, topiramate, or lamotrigine 1
Food decreases Cmax by 20% and delays Tmax by 1.5 hours but does not affect overall absorption—can be taken with or without food 1.